Esperion Therapeutics (NASDAQ:ESPR) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.

Several other research analysts also recently commented on ESPR. Citigroup downgraded shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $77.00 to $96.00 in a research report on Monday, January 22nd. BidaskClub downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Chardan Capital restated a “neutral” rating and set a $75.00 price objective (up from $20.00) on shares of Esperion Therapeutics in a research report on Tuesday, December 5th. Bank of America upgraded shares of Esperion Therapeutics from a “neutral” rating to a “buy” rating and set a $76.00 price objective for the company in a research report on Friday, January 5th. Finally, Stifel Nicolaus set a $105.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a research report on Monday, January 15th. Six analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $77.23.

Esperion Therapeutics (NASDAQ:ESPR) opened at $70.46 on Friday. Esperion Therapeutics has a 1 year low of $13.41 and a 1 year high of $82.18.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.07). During the same quarter last year, the business posted ($0.77) EPS. analysts expect that Esperion Therapeutics will post -7.3 earnings per share for the current year.

In other news, Director Nicole Vitullo sold 9,326 shares of the company’s stock in a transaction on Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total transaction of $502,205.10. Following the completion of the transaction, the director now directly owns 2,472 shares in the company, valued at $133,117.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 32.50% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in ESPR. Schwab Charles Investment Management Inc. increased its holdings in shares of Esperion Therapeutics by 23.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 68,275 shares of the biopharmaceutical company’s stock worth $3,160,000 after buying an additional 13,146 shares in the last quarter. Swiss National Bank increased its holdings in shares of Esperion Therapeutics by 18.5% during the second quarter. Swiss National Bank now owns 26,300 shares of the biopharmaceutical company’s stock worth $1,217,000 after buying an additional 4,100 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Esperion Therapeutics by 5.3% during the second quarter. Alliancebernstein L.P. now owns 30,070 shares of the biopharmaceutical company’s stock worth $1,392,000 after buying an additional 1,500 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of Esperion Therapeutics by 382.0% during the second quarter. Teachers Advisors LLC now owns 142,483 shares of the biopharmaceutical company’s stock worth $6,594,000 after buying an additional 112,920 shares in the last quarter. Finally, TIAA CREF Investment Management LLC increased its holdings in shares of Esperion Therapeutics by 3.0% during the second quarter. TIAA CREF Investment Management LLC now owns 39,074 shares of the biopharmaceutical company’s stock worth $1,808,000 after buying an additional 1,148 shares in the last quarter. Institutional investors own 92.98% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “ValuEngine Upgrades Esperion Therapeutics (ESPR) to “Hold”” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/02/04/valuengine-upgrades-esperion-therapeutics-espr-to-hold.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.